The hypothalamic-pituitary-adrenal axis is a key mediator of the stress response in humans. The corticotropin-releasing factor (CRF) type 1 receptor (CRFR-1) in the pituitary gland is a gatekeeper for that response, and the CRFR-1 receptor is also present in many other mood-and cognition-related neural structures. Behaviorally, a number of relationships between stress and psychiatric disorders can be observed: chronic or repeated stress is associated with onset of depression; stressors can cause a recovering alcoholic to relapse; overactive stress responses mark many anxiety disorders; and insomnia can arise from an overactive stress response. Thus, a CRFR-1 antagonist could be useful for treating or preventing the consequences of CRF-mediated stress in depression, anxiety, insomnia, and substance abuse.
( Figure 1D) . 1 These glands then release cortisol, which not only helps the body to mobilize energy for the classic fight-or-flight response, but also affects the brain. 1 A key brain structure affected by cortisol is the hippocampus. The hippocampus normally can suppress the HPA axis through a pathway to the CRF-containing cells in the hypothalamus. 1 However, chronic stress and cortisol can damage the hippocampus (cellular atrophy, reduced neurogenesis, and shrunken hippocampi have been observed). 1, 3 The hippocampus, thus impaired by stress, cannot sufficiently regulate the HPA axis. Left unchecked by the hippocampus, the HPA stress circuit can ramp up to excessively high levels-an unfortunate feed-forward cycle.
Corticotropin-Releasing Factor Type 1 Receptors (Outside the HypothalamicPituitary-Adrenal Axis)
Besides the key role of CRFR-1 receptors in the HPA axis, CRFR-1 receptors also are widely distributed throughout the primate brain, 2, 4, 5 though exact anatomical reports vary due to methodological differences.
Some roles for neural CRFR-1 may be ancillary to the HPA axis, since the amygdala and the hippocampus-structures that regulate the HPA-contain CRFR-1 receptors. 2, 5 However, these structures also have functions unrelated to the HPA. In animals, anxious or alcohol-seeking behaviors can be altered by infusion of CRF or a CRFR-1 antagonist into the amygdala. The hippocampus plays a role in higher cognitive function. 6 Infusion of CRF into the hippocampus of animals can facilitate learning, but a CRFR-1 antagonist can block that effect. 7 Other roles for neural CRFR-1 are more distinctly distal from the HPA axis, but are still highly relevant to psychiatric disorders. The serotonin (5-HT)-containing raphe nucleus of the primate brain has been reported to contain CRFR-1. 4 Similarly, the norepinephrine (NE)-containing locus coeruleus of the primate brain apparently contains CRFR-1 receptors. 2 Localization of CRFR-1 receptors in the primate brain also hints at a possible role in memory. The medial septum/diagonal band complex and the nucleus basalis of Meynert are rich in CRFR-1 receptors 4 and also contain cholinergic neurons that are thought to modulate attention and arousal. The pathology of Alzheimer's disease includes a pronounced loss of cholinergic neurons from the nucleus basalis of Meynert.
Finally, localization of CRFR-1 receptors in the primate brain implies a role in sensory function, motor function, sensorimotor integration, and other functional systems. 2, 4 The CRFR-1 receptor is abundant in the cerebellum, cerebral cortex, basal forebrain, portions of the basal ganglia, and thalamus. 2, 4 
STRESS CIRCUITRY AND DEPRESSION
The Hypothalamic-Pituitary-Adrenal Axis, the Hippocampus, and Cognition in Depression
Hippocampal and Hypothalamic-PituitaryAdrenal Axis Abnormalities Abnormally small hippocampi and altered HPA axis activities have been observed in patients with major depressive disorder (MDD), though it is unclear whether the diminished hippocampus is the cause of the altered HPA activity, the result of excessive HPA activity, or a combination of both. 1 Each case may be unique. Whatever the cause, antidepressants can renormalize HPA activity and can induce neurogenesis in the hippocampus. 1, 8 Such restoration is important because a diminished hippocampus has repercussions beyond its implications for HPA axis regulation. The hippocampus plays a role in higher cognitive function, including learning and memory. 6 Moreover, the hippocampus appears to be involved in emotional processing, since antidepressants increase neurogenesis in the hippocampus and since ablating the hippocampus blocks the mood-elevating effects of antidepressant treatment. 8 Table 1 summarizes evidence of HPA axis dysregulation in depressed patients. 1 either genetic or environmental causes-nature, nurture, or both. Carriers of a gene for an altered neurotrophic factor are at risk for smaller hippocampi and for depression. 9 Similarly, women who were abused as children are at elevated risk for adulthood depression, 10 and women who were abused as children and who have MDD have smaller hippocampi than their neverabused, depressed counterparts.
D i m i n i s h e d h i p p o c a m p a l v o l u m e s i n depressed patients evidently can arise from

HPA Axis Dysregulation Observed in Some Depressed Patients
11
The Hippocampus and Cognitive Dysfunction Diminished hippocampal volumes may be associated with the cognitive deficits often observed in depression: depressed individuals may report an impaired ability to think, concentrate, or make decisions, or they may easily be distracted or complain of memory difficulties. 12 In patients with MDD, a smaller hippocampus correlated with more errors on a cognitive test (card sorting).
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Glucocorticoids, Stress, and Serotonin Networks in Depression
Serotonin Circuits and Depression Symptoms 5-HT is one of the primary neurotransmitters implicated in depression. Most neural serotonin is synthesized by cells in the raphe nuclei of the brainstem. Serotonergic cells in the raphe nuclei send projections that innervate and affect many brain regions associated with symptoms of depression ( Figure 2 ).
14,15 Serotonergic function is thought to be reduced in depressed patients; selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are widely used in attempts to restore that function.
Serotonin, Stress, Glucocorticoids, and Corticotropin-Releasing Factor Type 1 Receptors Serotonergic systems are susceptible to stress and cortisol. Acute stress causes cells in the raphe nuclei to release 5-HT, but long-term stress can deplete these stores. 16 This depletion may be permanent: in monkeys that were stressed for 14 months and then allowed to recover for 14 months, levels of 5-HT in the ventral prefrontal cortex never returned to prestress levels. 16 Stress may affect raphe cells through glucocorticoid receptors, which are present in the serotonergic cells 17 and which affect the amounts and types of proteins produced by these cells. An important protein affected by glucocorticoid treatment is tryptophan hydroxylase, the enzyme that synthesizes 5-HT. Chronic treatment with glucocorticoids reduces by sixfold the amount of messenger ribonucleic acid for tryptophan hydroxylase. 18 The projected downstream effects are less tryptophan hydroxylase protein and, thus, less 5-HT-perhaps eventually resulting in the symptoms of depression shown in Figure 2 . Besides these downstream effects, the primate raphe nuclei also have been reported to contain CRFR-1 receptors, 4 though reports from other researchers are conflicting. 2 In rats, infusion of CRF into the raphe nucleus causes dose-dependent decreases of 5-HT release into the pleasure-related nucleus accumbens ( Figure 2B ). 19 Pretreatment with a CRFR-1 antagonist abolished this effect. 19 The researchers in this experiment suggested that these CRFR-1-modulated effects on the serotonergic output to the nucleus accumbens had the potential to modify a suite of behaviors related to anticipation, motivation, reward, and depression.
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FIGURE 2.
Relationships between symptoms of depression and some serotonergic projections from a raphe nucleus* 
CNS Spectr
The Serotonin Reuptake Transporter and Stress After a raphe cell releases 5-HT to its targetssuch as the anatomical locations shown in Figure  2 -the cell uses the serotonin reuptake transporter (SERT) to recover the 5-HT for the next firing. The SERT protein is the well-known target of SSRIs and SNRIs; these drugs block cellular reuptake of 5-HT so that the neurotransmitter signal is magnified, as 5-HT remains in the synaptic cleft for longer durations. The SERT protein is, therefore, of obvious interest in depression; it is also strongly implicated in models of stressinduced onset of depression.
In one study, 20 26-year-old subjects were interviewed to assess whether any depression had occurred during the past year. Stressful life events occurring after the 21 st birthday and before the 26 th birthday were assessed using a life-history calendar. Those stressful events were defined and grouped; they included issues related to employment, finances, housing, health, and relationships. 20 In genetic carriers of the short form of the SERT, depression was more likely to occur when more stressful life events had occurred. There was a rough dose-response curve, with stress as the "dose" and depression as the "response. " 20 No such relationship was observed in subjects with the genotype homozygous for the long form of the transporter. 20 Genotype for the short-form transporter alone, however, was not sufficient to predict the onset of depression. The contribution of stress was necessary to observe the relationship.
Another study 21 found that the short SERT allele is associated with production of significantly higher levels of glucocorticoids and with poorer scores on a test of verbal learning. A significant interaction of the short allele and higher glucocorticoid levels was associated with smaller hippocampal volume. This relationship was stronger among short allele carriers than in noncarriers. 21 The subjects in this study were healthy older adults-not depression patients-but the results still may offer some biochemical rationale for the depression study. 20 
Glucocorticoids, Stress, and Norepinephrine Networks in Depression
Norepinephrine Circuits and Depression Symptoms Another neurotransmitter implicated in depression is NE (also called noradrenaline). Most neural NE is synthesized by cells in the locus coeruleus of the brainstem. Noradrenergic cells in the locus coeruleus send projections that innervate and affect several brain regions associated with symptoms of depression ( Figure 3 ).
14,15
Noradrenergic function is thought to be reduced in some depressed patients. Therefore, some antidepressants seek to restore noradrenergic function. SNRIs primarily target 5-HT, but they also elevate synaptic NE levels. The NE and dopamine reuptake inhibitor bupropion elevates not only NE but also dopamine synaptic levels.
Norepinephrine Levels, Stress, and Glucocorticoids In rodents, an acute stressor, such as unaccustomed handling or immobilization, causes release of NE into brain regions such as the prefrontal cortex, striatum, and hippocampus, 22 and into the hypothalamus. 23 However, this response is blunted by chronic stress or by its chemical equivalent (long-term treatment with a glucocorticoid). 23 Like raphe neurons, neurons in the locus coeruleus contain glucocorticoid receptors, which may mediate stress-related changes in noradrenergic function. 24 This relationship, however, is not yet as clearly elucidated as in the case of serotonergic systems. Relationships between depression symptoms and some noradrenergic projections from the locus coeruleus *14,15 * Boxed items contain symptoms from the formal diagnostic criteria for MDD.
(A) Cognitive dysfunction in depression may be related to noradrenergic projections to the dorsolateral prefrontal cortex, a brain region that is key for attention, working memory, decision making, and skill acquisition. (B) The hypothalamus is a regulator of homeostatic functions, and its noradrenergic innervation may be related to the vegetative symptoms of depression, such as loss of weight or appetite and insomnia or hypersomnia. (C) Noradrenergic innervation of the cerebellum, a motor-regulating brain structure, may be related to physical fatigue. 
CNS Spectr
As previously discussed, the NE-containing locus coeruleus of the primate brain also apparently contains CRFR-1 receptors. 2 
Glucocorticoids, Stress, and Dopamine Networks in Depression
Dopamine Circuits and Depression Symptoms A third neurotransmitter implicated in depression is dopamine. Dopamine-synthesizing cells in the ventral tegmental area of the brainstem innervate and affect several brain regions associated with symptoms of depression ( Figure  4 ).
14,15 Dopaminergic function is thought to be reduced in depressed patients. As aforementioned, bupropion targets NE and dopamine in an attempt to restore the function of these neurotransmitter networks.
Dopamine Levels, Stress, and Glucocorticoids In rats, acute stressors generally cause a release of dopamine to the nucleus accumbens and prefrontal cortex. 25 However, this is true only when the stressor is controllable or escapable; once the stressor changes to one that the rat cannot escape, dopamine tone in the nucleus accumbens is attenuated. 26 As with serotonergic and noradrenergic systems, enhanced release of dopamine in the nucleus accumbens with acute stress changes to suppressed release of dopamine with chronic stress. 27 Animals exposed to such chronic stress are hyporeactive to pleasurable stimuli, which is a basis for depression and which is related to dopamine in the nucleus accumbens. 26 Although dopamine release in response to acute stress is apparently independent of the HPA axis, 28 the long-term downregulation of dopamine systems with stress may be mediated through glucocorticoids. The ventral tegmental area is dense with glucocorticoid receptors. 29 When corticosterone was chronically administered to two strains of rats known to differ in their HPA axis activities and in their behavioral responses to drugs of abuse (which act at dopamine terminals in the nucleus accumbens), differences were seen between the animal types in the responding levels of tyrosine hydroxylase, a key enzyme for the synthesis of dopamine. 29 After chronic corticosterone, the two types of rats also exhibited behavioral differences to pleasure-inducing (dopaminergic) drugs of abuse. This suggests that certain individuals may have a genetic susceptibility (related to their HPA axis) to stress-induced changes in dopamine function, just as was seen for stress-induced depression in carriers of certain types of the SERT. Table 2 summarizes the implications for a CRFR-1 antagonist for the treatment of stressaffected neurocircuitry in depressed patients.
STRESS CIRCUITRY AND ANXIETY
The Family of Anxiety Disorders
Anxiety disorders occur in a broad spectrum of subtypes, including panic disorder, phobias, obsessive-compulsive disorder, generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). 30 Since these anxiety disorders share many clinical characteristics, it is perhaps not surprising that they also share many biological features. The anxiety/ fear circuitry of these disorders, centered on the amygdala, is of interest in relation to CRF antagonists; this circuitry will be discussed in the sections that follow. The Hypothalamic-Pituitary-Adrenal Axis and the Amygdala in Anxiety Disorders Amygdala-Centered Anxiety Circuits As discussed earlier, the amygdala integrates sensory and cognitive information, and then determines whether a fear response should be triggered (including activation of the HPA axis). Other amygdala-centered circuits, which are summarized in Figure 5 , may be overactivated in specific anxiety disorder subtypes. 31 Amygdala-centered circuits are often targets of anxiolytic medications. Serotonergic afferents project from the raphe to the amygdala and can dampen activity of the amygdala. Injection of an SSRI into the amygdala of animals can reduce anxious behavior, 32 and SSRIs are used for treatment of GAD. The amygdala also contains circuitry using γ-aminobutyric acid (GABA), the principal inhibitory neurotransmitter of the brain, which normally reduces the activity of the amygdala. Injection into the amygdala of an indirect GABA agonist, such as the benzodiazepine diazepam, reduces anxious behaviors in animals, 33 and this class of agent is widely used in the treatment of anxiety disorders.
The amygdala not only activates the CRFcontaining HPA axis; it also contains CRFR-1 receptors 2,5 and has CRF-containing projections of its own, as shown in Figure 6 . 34, 35 In animals, stress increases the concentration of CRF in the amygdala, and microinjection of CRF into the amygdala generates anxiety-like behaviors. 34 Conversely, anxiety-like behaviors can be reduced by administering a CRF receptor antagonist into the amygdala. 34 The dorsal raphe nucleus receives CRF projections from the amygdala ( Figure 6B) . 34 As previously noted, the primate raphe nuclei apparently contain CRFR-1 receptors. 4 Infusion of low concentrations of CRF into the dorsal raphe nucleus reduces the activity of its serotonergic cells, apparently through action at the CRFR-1 receptor. 36 Thus, a CRFR-1 antagonist could ameliorate anxiety-related dysregulation at the raphe nucleus, upstream of the effects mediated by SSRIs.
The CRF connections from the amygdala to the noradrenergic neurons of the locus coeruleus ( Figure 6A ) are likely mediators of anxiety. As illustrated in Figure 5B , excessive noradrenergic output from the locus coeruleus to the amygdala can result in peripheral/autonomic overdrive symptoms; moreover, this circuit also • is associated with specific symptoms of depression in certain brain regions • may result from chronic stress/glucocorticoids or from CRF at the raphe • in some cases may be related to the presence of the short SERT form, resulting in susceptibility to stressinduced depression, higher levels of plasma cortisol, and smaller hippocampal volumes Depression, stress, and norepinephrine or dopamine: diminished noradrenergic and/or dopaminergic activity • is associated with specific symptoms of depression in certain brain regions • may result from chronic stress/glucocorticoids * Implications: Unlike antidepressants that target the outcome effects of symptoms related to serotonin, norepinephrine, and/or dopamine deficiencies, a CRFR-1 receptor antagonist could renormalize stress-related depression nearer to the source, upstream of neurotransmitter dysregulation.
HPA=hypothalamic-pituitary-adrenal; CRF=corticotropin-releasing factor; CRFR1=corticotropin-releasing factor type 1; SERT=serotonin reuptake transporter. can trigger "central" symptoms of anxiety, such as nightmares, hyperarousal, flashbacks, and panic attacks. 30 Hypothetically, these symptoms may be mediated in part by excessive noradrenergic input to α 1 -and β 1 -adrenergic receptors in the amygdala; in some patients, these symptoms can be reduced by treatment with β 1 -adrenergic blockers, such as propranolol or metoprolol, or with α 1 -adrenergic blockers, such as prazosin. 30 In animals, stress increases the concentration of CRF in the locus coeruleus, and microinjection of CRF into the locus coeruleus induces anxiety-like behavior. 34 These CRF-induced anxious behaviors can be reversed by infusion of CRFreceptor antagonists into the locus coeruleus. 34 Benzodiazepines can attenuate some of the anxiogenic effects of CRF, possibly partly mediated through reduction of the concentration of CRF in the locus coeruleus. 34 Thus, a CRF antagonist for the treatment of anxiety could ameliorate dysregulation at the locus coeruleus, upstream of the effects mediated by benzodiazepines or antinoradrenergic medications.
An anatomical map of the projections discussed in this section is shown in Figure 7 . 31 The Locus Coeruleus and CorticotropinReleasing Factor Type 1 Receptors in Anxiety As discussed in the preceding section, the locus coeruleus has key CRF-related and anxietyrelated connections to the amygdala. However, the locus coeruleus also innervates other areas of the brain to regulate arousal and fear-related behaviors, some of which are modulated through CRFR-1 receptors in coerulear neurons.
• Hippocampus: When CRF was applied directly to the locus coeruleus of rats, the firing rate of its neurons increased, and concomitant release of NE into the hippocampus also was increased. 37 This effect could be reversed by pretreatment with a CRF antagonist. 37 In PTSD, the hippocampus may be involved in the reexperiencing of traumatic memories ( Figure 5D ) and therapeutic strategies may include anti-noradrenergic agents.
• Prefrontal cortex: When rats are subjected to a fear-inducing stressor (handling), NE is released to the medial prefrontal cortex,
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FIGURE 6.
Anxiety-related projections of the amygdala that contain CRF
34,35
CRF=corticotropin-releasing factor; HPA=hypothalamic-pituitary-adrenal. a region that is involved in cognition and that performs abnormally during emotional cognitive tasks in PTSD-afflicted patients. 39 When a CRFR-1 receptor antagonist was applied directly to the locus coeruleus of rats, the extracellular levels of NE in the medial prefrontal cortex were unaffected; however, when the rat was then subjected to handling, the usual release of NE to the medial prefrontal cortex was suppressed. 38 Thus, a CRFR-1 receptor antagonist could especially be useful for the treatment of abnormally functioning locus coeruleus cells in patients with PTSD.
Anxiety Circuits and the HypothalamicPituitary-Adrenal Axis in Anxiety Disorder Patients
In patients with different anxiety disorders, researchers have observed various abnormalities in HPA axis parameters and in neural anxiety circuits. 34, [40] [41] [42] HPA axis dysregulation is particularly problematic in PTSD. For example, the cerebrospinal CRF levels in 11 nondepressed PTSD patients (veterans) who had not used alcohol for at least 6 months and in 12 matched healthy controls over 6 daytime hours were measured and compared with controls: PTSD patients had significantly higher levels of CRF (P<.04) but no P<.04) but no P difference in cortisol levels. 43 Table 3 summarizes implications for a CRFR-1 antagonist for the treatment of overactive stress neurocircuitry in anxiety-disordered patients.
STRESS CIRCUITRY AND INSOMNIA
We have already discussed how hypothalamic 5-HT and NE may be related to insomnia in depression, and difficulty sleeping is a symptom of GAD, but insomnia also can occur outside of other psychiatric or medical disorders; in such cases, it is called "primary insomnia. " The types and causes of insomnia are diverse, but some may be related to CRF.
Daily Rhythms Related to CorticotropinReleasing Factor and/or Stress
C R F, AC T H , a n d c o rt i s o l a r e n o t o n l y secreted in response to stressors; these hormones also are secreted in a normal daily rhythm. Because the cycle normally runs so that cortisol peaks just before waking, it can be thought of as a pattern that helps the body to mobilize energy to deal with the "stress" of waking up. Cortisol and ACTH fall to a nadir at night to allow the onset of sleep. 44, 45 Rhythms also exist in two previously discussed neurotransmitter systems: the noradrenergic projections from the locus coeruleus and the dopaminergic projections from the ventral tegmental area. In the cortex, these noradrenergic and dopaminergic systems help regulate alertness, which partially explains the involvement of both systems for the symptom of "problems concentrating" in depression (Figures 3 and 4) . Brain levels of neurotransmitters cannot easily be measured in humans, Figure 8 are extrapolated from studies of rats; 46, 47 however, since rats are nocturnal, the pattern is inverted for the diurnal behavior of humans. These circuits and rhythms partially explain why two principal stimulants used as wake-promoting agents are methylphenidate and amphetamine, which act at cortical noradrenergic and dopaminergic terminals. 48 Moreover, as discussed above, NE and dopamine are released in response to short-term stress; thus, stress-induced hyperarousal of the cortical noradrenergic and dopaminergic systems may explain some instances of insomnia. Figure 6 shows an anxiety-related circuit: the locus coeruleus is innervated by CRF-containing projections from the amygdala, and the locus coeruleus, in turn, sends noradrenergic projections to the amygdala. In animals, it has been shown that this circuit is quieted at night and is more active during the day. 49 For humans, this implies that anxiety is (or should be) suppressed at night in order for normal sleep to occur. Figure  9 summarizes the anatomy of the sleep-related circuits discussed in this section that exhibit daily rhythms, are susceptible to stress or anxiety, and involve CRF or the HPA axis.
Alterations Related to CorticotropinReleasing Factor in Insomnia
A variety of alterations in HPA axis components have been observed in insomniacs, and forced changes in HPA parameters can disrupt the sleep of control subjects (Table 4) .
Insomnia is often treated with benzodiazepines, such as triazolam or temazepam, or with the nonbenzodiazepine hypnotics zolpidem or eszopiclone. Such agents can affect the HPA axis. When poor sleepers were given benzodiazepines for 3 weeks, total overnight urinary cortisol was lower during active treatment, but then significantly rebounded to above-baseline levels upon drug discontinuation. 50 Sleep-inducing benzodiazepines also can inhibit peak serum cortisol levels and ACTH after CRF administration to healthy volunteers. 50 Table  5 summarizes implications for a CRFR-1 antagonist for the treatment of insomnia.
induce drinking behavior; once ingested, alcohol has the same general effect as stress on the HPA axis; in heavy drinkers, plasma ACTH levels are elevated, but cortisol levels are lower, 51 a dysregulation that is thought to originate at the level of CRF-secreting neurons 52 ; after cessation of drinking in the detoxification process, activity of the HPA axis can be elevated for weeks; and in recovered alcoholics, stress can induce relapse. 52 The elevated anxiety that is a hallmark of alcohol withdrawal is mediated through CRF at the amygdala: during withdrawal, CRF concentration or CRF release is increased in the amygdala and the bed nucleus of the stria terminalis, and the anxiety can be blocked by CRF antagonism in the amygdala. 53 Drinking behavior during this period of alcohol withdrawal also is CRF-related; when animals are forced into dependency and then forced into withdrawal (by adding and then removing atmospheric alcohol), their rates of alcohol self-administration are much higher than in animals that had never been dependent. 54 However, systemic treatment with a CRFR-1 antagonist reduces the rate of selfadministration during withdrawal. 54 This effect is apparently mediated through the amygdala, since microinjections of a CRF receptor antagonist into the amygdala (but not into the bed nucleus of the stria terminalis or into the nucleus accumbens) similarly reduce excessive alcohol self-administration rates during withdrawal. 55 Three types of environmental stimuli can trigger relapse in previously alcohol-dependent individuals or animals: small, "priming" doses of alcohol; conditioned cues associated with past availability of alcohol; and stress. 53 The opioid receptor antagonist naltrexone, which is clinically used to treat alcoholism, can block cue-induced relapse but not stress-induced relapse. 53 Conversely, stressinduced relapse, but not cue-induced relapse, can be blocked by a CRF antagonist. 53 Because adrenalectomy does not affect stress-induced relapse of alcohol-seeking behavior, CRF-mediated relapse must be strictly a function of the central nervous system (ie, not mediated by the HPA axis).
53 Table  6 summarizes implications for a CRFR-1 antagonist for the aid of alcoholics undergoing withdrawal or striving to avoid relapse.
OVERLAP OF DEPRESSION, ANXIETY, ALCOHOLISM, AND INSOMNIA ALCOHOLISM, AND INSOMNIA
Depression and Anxiety
Comorbidities between depression and anxiety disorders are very common. In a study of 255 
Summary: Stress Circuitry and Insomnia
*
Daily rhythms exist in CRF, ACTH, and cortisol; these rhythms should allow cortisol to fall to a nadir before sleeping and should drive cortisol to peak for waking Daily rhythms exist in neural noradrenergic and dopaminergic systems; activity of these systems is high during the day but should go quiescent at night to allow sleep Alterations in the HPA axis have been observed in insomniacs Forced alterations to the HPA axis can cause sleep disturbances in control subjects Pharmacologically, insomnia can be treated by hypnotics; these agents can help to renormalize HPA axis parameters * Implications: In some cases of insomnia, a CRFR-1 receptor antagonist could help to alleviate stress-or anxiety-related hyperarousal or could help to renormalize disordered HPA axis parameters.
CRF=corticotropin-releasing factor; ACTH=adrenocorticotrophic-releasing factor; HPA=hypothalamic-pituitary-adrenal. 56 comorbid anxiety disorders were diagnosed in 50.6% of subjects; the breakdown of anxiety disorder subtypes is shown in Figure 10 . For the case of PTSD in particular, comorbidity with depression is especially common. In one study of 52 veterans with PTSD, 57 MDD occurred in 95% of patients at some point in their lifetime; 50% of patients had depression at the same time as their PTSD. Similarly, in a study of 677 depressed veterans, 58 36% screened positive for PTSD. More generally, in a study of 1,450 patients with depression, 46% had "anxious depression" (MDD with high levels of anxious symptoms but not with an actual comorbid anxiety disorder). 59 Compared with healthy controls (N=23), untreated depressed children (N=23) had a larger ratio of amygdalar volume to hippocampal volume. 60 Moreover, increased amygdala-to-hippocampus volume ratios were associated with increased severity of anxiety within depression. 60 For anxious varieties of depression, this anatomical phenomenon may suggest an enlarged/overactive amygdala, as discussed above for anxiety disorders; or an atrophied/insufficient hippocampus, as discussed above for depression; or a combination of both anatomical abnormalities.
Insomnia in Depression and Anxiety
Insomnia as a symptom of depression and anxiety disorders has already been discussed; however, it should be noted that the treatment of insomnia as a symptom of these disorders may enhance recovery in the primary disorder. When patients (N=545) with both MDD and insomnia received a morning SSRI (fluoxetine) and nightly hypnotic (eszopiclone) or nightly placebo, patients in the eszopiclone group experienced not only improved sleep quality, but also a faster onset of antidepressant response and a greater magnitude of the antidepressant effect. 61 Similarly, when patients with GAD and insomnia received an SSRI (escitalopram) and a nightly hypnotic (eszopiclone) or nightly placebo, the eszopiclone group experienced not only improved sleep quality, but also a faster and greater anxiolytic response. 62 These phenomena are depicted schematically in Figure 11 .
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Alcoholism and Mood Disorders
When alcohol dependence occurs at the same time as a mood disorder, the combination is extremely complicated for a clinician to manage; both conditions must be treated, but many anxiolytics and antidepressants should not be combined with alcohol. The co-occurrence of alcohol dependence with psychiatric disorders is fairly common, as was found by The National Comorbidity Survey (an exhaustive and well-known study of mood disorders and substance abuse in average United States citizens). 63 The percentages of subjects (of N=8,098 persons 15-54 years of age in the noninstitutionalized civilian population of the 48 contiguous states) who had a psychiatric disorder and who also were dependent on alcohol in the same year are shown in Figure 12 . 
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Phobias
Biological correlates of these comorbidities may even sometimes be physically observable. In subjects with histories of alcoholism, the hippocampal volume was 9% smaller in persons with PTSD than in those without PTSD (P=.002). P=.002). P 64 In nonalcoholic subjects, the PTSD-related difference in hippocampal volume had a trend in the same direction (3% smaller with PTSD) but did not achieve statistical significance. 64 Table 7 summarizes implications for a CRFR-1 antagonist for the treatment of comorbid psychiatric disorders discussed in this section.
RELATED: THE ARGININE VASOPRES-SIN TYPE 1B RECEPTOR
The promise of therapeutic efficacy of a CRFR-1 antagonist in stress-related psychiatric disorders has a potential competitor: an arginine vasopressin (AVP) type 1b (AVPR 1b ) receptor antagonist. Hypothalamic AVP acts synergistically with CRF to trigger ACTH secretion from the pituitary gland, as shown in Figure 13 . 52 Unlike CRF levels, AVP levels do not diminish upon exposure to prolonged stress; this may explain why both CRF and AVP apparently are needed for complete regulation of glucocorticoid secretion.
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FIGURE 12.
Prevalence of comorbid alcohol dependence among subjects with anxiety disorders (red) or depression (grey) 63 PTSD=posttraumatic stress disorder; GAD=generalized anxiety disorder. 
Dual regulation of ACTH release from the pituitary gland
ACTH=adrenocorticotropic hormone; CRF=corticotropin-releasing factor; AVP=arginine vasopressin; CRFR-1=corticotropin-releasing factor type 1 receptor; AVPR 1b =arginine vasopressin type 1b receptor. Summary: Overlap of Depression, Anxiety, Alcoholism, and Insomnia * Co-occurrence of depression with an anxiety disorder is fairly common; comorbid conditions may share biological characteristics of each disorder independently Insomnia is common within depression and generalized anxiety disorder; treating patients for both conditions can enhance recovery from the mood disorder Alcoholism is fairly common in depressed or anxietydisordered patients * Implications: Since a CRFR-1 receptor antagonist is potentially useful for the treatment of anxiety, depression, insomnia, and alcoholism, that antagonist would likely be useful for the treatment of common comorbidities among those disorders and might be more useful than an agent that was efficacious against only one of the disorders.
CRFR-1=corticotropin-releasing factor type 1. 
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Like CRF and CRFR-1, AVP and its 1b-type receptor are also found in other brain regions. Most notably (in relation to topics discussed in this column), some AVP-containing neurons originate from the bed nucleus of the stria terminalis and from the medial amygdala; these cells project to the lateral septum, ventral septal nucleus, lateral habenular nucleus, locus coeruleus, and hippocampus. 65 At these target structures, AVP is thought to exert its biological effects by binding to AVPR 1a and AVPR 1b receptors. 65 Functionally, an AVPR 1b receptor antagonist can suppress stress-related NE release from the locus coeruleus; behaviorally, an AVPR 1b antagonist can exert anxiolytic or antidepressant effects in animal models. 65 Thus, an AVPR 1b antagonist and a CRFR-1 antagonist might share similar clinical effects.
